When physicians ask us what makes our manufacturing partner different from other peptide suppliers, the answer starts with three letters: USP-797.
Most physicians have heard of USP-797 in the context of hospital pharmacies or sterile IV preparation. Fewer realize it directly applies to compounded injectable peptides — and that most suppliers in the compounded GLP-1 space are not operating under this standard.
Here is exactly what USP-797 certification means, why it matters clinically, and what it means for your practice when you prescribe a compounded peptide from Majestic.
What USP-797 Is
USP Chapter <797> is the United States Pharmacopeia's compendial standard for sterile compounded preparations — meaning any compounded product that will be injected, infused, or otherwise introduced into the body in a sterile manner. It is enforceable by the FDA and state boards of pharmacy.
The standard sets binding requirements for the physical environment where compounding occurs, the equipment used, personnel training and garbing, sterility testing, beyond-use dating, and quality management systems. These are not aspirational guidelines. They are the floor below which a facility cannot operate and legally dispense sterile compounded products.
The key distinction: Research-grade peptides — the kind sold for lab use — are not required to meet USP-797. Compounded peptides intended for patient injection are. A facility claiming to supply physician-grade compounded injectables that is not USP-797 compliant is operating outside the standard that governs sterile preparations.
What It Means in Practice: ISO Class 5
The most important physical requirement under USP-797 is that all sterile compounding occurs in an ISO Class 5 environment or better. ISO Class 5 is a cleanroom classification that specifies the maximum number of airborne particles permitted per cubic meter of air — 3,520 particles of 0.5 microns or larger.
In practical terms, this means every step of peptide preparation — mixing, reconstitution, and vialing — happens inside one of two controlled environments:
- Laminar Airflow Hoods (LAH): Horizontal or vertical airflow workstations that continuously sweep filtered air across the work surface, preventing particles and microorganisms from settling on the product
- Isolators: Fully enclosed, glove-box style systems that physically separate the operator from the product, eliminating the risk of human contamination entirely
Both create an environment where microbial contamination — the primary sterility risk in compounding — is systematically controlled rather than hoped away.
Why This Matters for Physician Practices
Compounded GLP-1 peptides are administered subcutaneously — they are injected. Any contamination in the compounding process does not simply result in a less effective product. It creates a direct patient safety risk.
The consequences of non-sterile injectable compounding are well documented in the medical literature and in FDA enforcement actions. Microbial contamination in compounded injectables has caused serious patient harm historically, which is precisely why the USP-797 standard exists and why FDA takes sterile compounding compliance seriously.
For prescribing physicians: When you prescribe a compounded injectable to a patient, you are making an implicit representation that the product meets the standards appropriate for its route of administration. Sourcing from a USP-797 certified facility is the most defensible position a physician can take.
Beyond the direct patient safety argument, there is a practical practice management consideration. In the event of an adverse event — however unlikely — the documentation trail matters. A USP-797 certified manufacturing source, with independently verified COAs and lot-level traceability, provides a foundation that non-certified sources cannot match.
What Most Peptide Suppliers Don't Tell You
The compounded GLP-1 market expanded rapidly in 2023 and 2024, and not all participants entered with the same infrastructure. A significant portion of the market is supplied from facilities that:
- Source API from overseas with minimal incoming quality control
- Operate compounding processes that are not USP-797 compliant
- Provide COAs that are either self-generated or unverifiable at the issuing laboratory
- Cannot accommodate facility visits because there is no facility to visit
None of this is necessarily illegal depending on how products are classified and labeled. But it represents a meaningful quality gap — and one that is invisible to most physicians unless they know the right questions to ask.
The Majestic Standard
Our manufacturing partner, based in South Carolina, operates under USP-797 certification. Every peptide we supply is prepared in an ISO Class 5 environment to injectable-grade standards. Every lot is independently tested by TrustPointe Analytics LLC or Chromate before it ships, with COAs that are verifiable directly at the issuing laboratory's portal — not through us.
We publish our pricing, our lab names, our lot numbers, and our verification codes. We welcome facility visits from any physician or investor who wants to see the operation in person. This is not standard practice in the industry. It should be.
Current lot verification: You can verify our active lot purity and identity right now at TrustPointeLIMS.com or chromate.org/verify using the access keys published on the main site. No account required.
The Bottom Line
USP-797 certification is not a marketing badge. It is the minimum standard that a facility should meet to legally and ethically compound sterile injectables for patient use. If your current peptide supplier cannot confirm USP-797 compliance at their manufacturing facility, that is a question worth asking before the next order.
If you want to see the facility, meet the team, and review the documentation before making any commitment, that is exactly what the Majestic program is built for.
Ready to verify it yourself?
Schedule a 15-minute intro call, request your free practice analysis, or book a facility visit in South Carolina. No commitment required for any of these.